Revotek Deploys Its Bioink Technology to Research Institutes | News


CHENGDU, China, April 29, 2021 / PRNewswire / - Recently, Revotek Co., Ltd. ("Revotek"), a vertically integrated biotech company specializing in 3D bioprinting, and the West China Hospital of Sichuan University, a leading research hospital in Chinahave reached an agreement in which the latter are to introduce cell encapsulation technology from Revotek or Biosynsphere for use in their basic and translational research in stem cell regenerative medicine. On April 22The instrument (biosynspherer) and its first batch of reagents and consumables were shipped to the laboratory of the West China Hospital of Sichuan University. Revotek's 3D blood vessel bioprinter is expected to be delivered to the hospital laboratory in the third quarter of 2021.

In the cooperation, Revotek offers training on biosynspheres, biosynsphere preparation as well as technical and hardware support.

About Revotek

Founded in 2014, Revotek offers life-saving 3D bioprinting technologies that enable the delivery of fully personalized healthcare solutions. Revotek has developed the world's first Biosynsphere technology, a universal bio-ink that enables framework-free bioprinting. Based on this technology, the 3D blood vessel bioprinter and bone repair devices are derived and developed, which are of great value for clinical applications. Revotek's technologies have been recognized as a breakthrough in regenerative medicine, and Revotek has over 200 patents pending worldwide.

About Biosynsphere®

Biosynsphere® is a cell encapsulation process and tool that meets the needs of academic research and clinical applications. The biosynsphere has good biological properties so that the enveloped cells can perform biological functions normally. It also has good mechanical properties that effectively protect the enveloped cells from mechanical damage. As a platform technology, Biosynsphere has potential for a variety of applications including in vitro 3D cell culture, in vitro construction of micro-tissues, in vivo repair of damaged tissues and organs, and organ reconstruction.

About the ongoing collaboration

in the April 2020an agreement between Revotek and the University of Tennessee Health Science Center (UTHSC) where Revotek provided 3D bio-printing and biosynsphere technologies and services to the UTHSC. This is the first commercial agreement for Biosynsphere technology. In 2017, the two parties became strategic partners in the scientific research and clinical application of stem cell regenerative medicine. Since then, they have worked together on many aspects, such as the FDA application of 3D bioprinted blood vessels for stem cells for clinical studies.

View original content to download multimedia: http://www.prnewswire.com/news-releases/revotek-deploys-its-bioink-technology-to-research-institutes-301279977.html

SOURCE Revotek Co., Ltd.


continue reading https://dailytechnonewsllc.com/revotek-deploys-its-bioink-technology-to-research-institutes-news/?feed_id=5923&_unique_id=61cea63d17889

Commentaires

Posts les plus consultés de ce blog

Projections for the gambling industry for 2022

Tremendous scope for India-US cooperation in health technology and pharma, says expert

Global Home Sleep Screening Wearable Devices Market Insights Report, Forecast to 2027 – KSU